



**FOR IMMEDIATE RELEASE**

Tokyo, May 25, 2021

**JT Terminates Exclusive License Agreement with EirGen Pharma for Calcifediol Extended-release Capsules (JTT-762)**

Japan Tobacco Inc. (JT) (TSE:2914) announced today that the company will discontinue the development of JTT-762 (RAYALDEE® Calcifediol Extended-release Capsules). JT also announced the termination of the license agreement with EirGen Pharma Ltd. (EirGen Pharma) .

JTT-762 is a novel extended-release formulation of the prohormone of calcitriol, the active form of vitamin D<sub>3</sub>, which is approved to treat secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency in the U.S. and 11 European countries. JT's decision to discontinue development of JTT-762 follows a comprehensive reconsideration of its development pipeline.

The effects of this termination of the exclusive license agreement on JT's business performance in this fiscal year will be immaterial.

**About EirGen Pharma Ltd.**

EirGen Pharma Ltd., established in 2005, is a world-leader in the development, registration, manufacturing and supply of high-potency pharmaceutical products to global markets. The company is headquartered Waterford, Ireland.

For more information, visit [www.eirgen.com](http://www.eirgen.com).

###

*Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 58,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under the Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses.*

*For more information, visit <https://www.jt.com/>.*

**Contact for Japan Tobacco Inc.:**

Dinesh Babu Thotakura, General Manager

Media and Investor Relations Division

Japan Tobacco Inc. Tokyo: +81-3-6636-2026

E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)